Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Phase 2

Recruiting

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Placebo
Drug: Sintilimab

First Posted Date: 2024-02-05

Last Posted Date: 2024-02-05

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 104

Registration Number: NCT06240689

Locations: 🇨🇳
The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sintilimab
Drug: Anlotinib

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-25

Lead Sponsor: Ningbo No.2 Hospital

Target Recruit Count: 30

Registration Number: NCT06221462

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: Recurrent Glioblastoma

Interventions: Drug: Sintilimab
Radiation: Low-dose Radiotherapy

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 20

Registration Number: NCT06220552

Locations: 🇨🇳
Yingpeng Peng, Zhuhai, Guangdong, China

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: C019199
Drug: Sintilimab

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-25

Lead Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd.

Target Recruit Count: 155

Registration Number: NCT06220318

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: node-sparing short-course radiotherapy
Drug: Sintilimab
Drug: Capecitabine
Drug: Oxaliplatin
Procedure: TME surgery
Procedure: watch and wait

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Jinhua Central Hospital

Target Recruit Count: 37

Registration Number: NCT06204094

Locations: 🇨🇳
Zhejiang University Affiliated Jinhua Hospital, Jinhua, Zhejiang, China

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Phase 2

Not yet recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Golidocitinib
Drug: Sintilimab
Drug: platinum doublet chemotherapy

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT06198907

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: sintilimab

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 31

Registration Number: NCT06190639

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Phase 3

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma Thoracic Stage IV
Esophageal Squamous Cell Carcinoma Thoracic Stage II
Esophageal Squamous Cell Carcinoma Thoracic Stage III

Interventions: Drug: sintilimab

First Posted Date: 2023-12-08

Last Posted Date: 2023-12-08

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 400

Registration Number: NCT06161909

Locations: 🇨🇳
Fujian, Fujian, China

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Chemotherapy
Drug: Sintilimab

First Posted Date: 2023-12-01

Last Posted Date: 2023-12-01

Lead Sponsor: Fudan University

Target Recruit Count: 182

Registration Number: NCT06152978

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Phase 2

Recruiting

Conditions: Lung Squamous Cell Carcinoma

Interventions: Radiation: low-dose radiation therapy and stereotactic body radiation therapy
Drug: chemotherapy
Drug: Sintilimab

First Posted Date: 2023-11-08

Last Posted Date: 2024-08-13

Lead Sponsor: Sichuan University

Target Recruit Count: 114

Registration Number: NCT06121505

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy